Factors and outcomes associated with improved left ventricular systolic function in patients with cardiomyopathy.
Dylan Scott EigerLurdes Y T InoueQijun LiGust BardyKerry LeeJeanne PooleDaniel MarkZainab SamadDaniel FriedmanDaniel FishbeinGillian SandersSana M Al-KhatibPublished in: Cardiology journal (2021)
About a third of patients in this analysis, who were randomized to placebo or an ICD in SCD-HeFT, had a significant improvement in LVEF during follow-up; improvement in LVEF was associated with improved survival but not with cause-specific death, and with decreased likelihood of receiving appropriate ICD shocks.
Keyphrases
- left ventricular
- heart failure
- end stage renal disease
- double blind
- newly diagnosed
- blood pressure
- chronic kidney disease
- phase iii
- placebo controlled
- prognostic factors
- acute myocardial infarction
- open label
- randomized controlled trial
- hypertrophic cardiomyopathy
- adipose tissue
- mitral valve
- patient reported outcomes
- type diabetes
- cardiac resynchronization therapy
- aortic stenosis
- phase ii
- coronary artery disease
- patient reported